bims-glumda Biomed News
on CGM data in management of diabetes
Issue of 2026–02–22
seventeen papers selected by
Mott Given



  1. Diabet Med. 2026 Feb 18. e70267
       AIMS: Continuous glucose monitoring (CGM) systems have become important technologies to improve glycaemia in people with type 1 diabetes (T1D). However, it has been shown that during rapid glucose change, sensor performance can deteriorate. Comparative data on sensor performance during high rates of glucose change, such as during exercise, between a real-time continuous glucose monitor (rtCGM) and an intermittently scanned continuous monitor (isCGM) remain limited.
    METHODS: Twenty-two people with T1D (8 women, age 42 ± 11 years, HbA1c 59 ± 8 mmol/mol (7.6 ± 0.8%)) simultaneously used an rtCGM (Dexcom G6) and an isCGM (Freestyle Libre 1). Sixty-minute exercise sessions were performed on a cycle ergometer at moderate intensity, and glucose values from both CGM systems were compared against capillary reference blood glucose measurements (EKF S-Line; EKF Diagnostics, Germany). Data were assessed using the Median Absolute Relative Difference (MedARD) with interquartile range, as well as the Diabetes Technology Society Error Grid (DTS EG).
    RESULTS: During exercise, the MedARD was 14.6% [7.0;23.8] for rtCGM (2304 comparison points) vs. 11.6% [5.6;19.6] for isCGM (2266 comparison points) (p < 0.0001). When stratified by glycaemic range, the MedARD was 39.2% [31.8;46.8] vs. 27.0% [17.0;34.6] for time below range (<70 mg/dL) (p = 0.0001), 16.1% [8.1;24.8] vs. 12.8% [6.4;20.4] for time in range (70-180 mg/dL) (p < 0.0001) and 9.5% [4.7;16.0] vs. 8.0% [3.8;13.7] for time above range (>180 mg/dL) (p = 0.0064) for rtCGM vs. isCGM.
    CONCLUSION: In this head-to-head comparison of rtCGM and isCGM, isCGM demonstrated superior performance during exercise in adults with T1D.
    Keywords:  continuous glucose monitoring; exercise; type 1 diabetes
    DOI:  https://doi.org/10.1111/dme.70267
  2. Br J Nurs. 2026 Feb 19. 35(4): 192-198
       BACKGROUND: There have been many recent advances in diabetes technology, and continuous glucose monitoring (CGM) systems have grown in use and popularity.
    AIMS: This study evaluated the accuracy and efficacy of the Yuwell Anytime CT3 CGM system in participants with type 2 diabetes.
    METHODS: Forty participants were recruited to take part. They were asked to monitor their glucose levels for 10 days using two devices, a continuous glucose sensor (Yuwell Anytime) and an Accu-chek blood glucose finger-prick test.
    FINDINGS: The overall mean absolute relative difference (MARD) between the two measurement systems was 6.9%, with a Pearson correlation coefficient of 0.92 (P<0.0001). The reliability of the sensor was preserved across the full observed range of glucose concentrations.
    CONCLUSIONS: The Yuwell Anytime had excellent agreement with a standard finger-prick blood test of glucose in free-living type-2 diabetics.
    Keywords:  Accuracy; Bluetooth; Continuous glucose monitor; Diabetes; Efficacy; MARD; Transmitter
    DOI:  https://doi.org/10.12968/bjon.2026.0009
  3. Endocr Pract. 2026 Feb 17. pii: S1530-891X(26)00800-1. [Epub ahead of print]
       OBJECTIVES: Continuous glucose monitoring (CGM) improves glycemic control in patients with type 2 diabetes (T2D), but real-world sustainability following hospital discharge remains unclear. We evaluated factors associated with CGM continuation after transitioning from structured study support to routine care.
    METHODS: This 12-week observational follow-up study included hospitalized patients with insulin-requiring T2D (HbA1c > 8.0%) who had received study-provided CGM for 12 weeks post-discharge. After the intervention, participants could continue CGM through usual care if desired. Primary outcomes included CGM continuation, glycemic parameters, healthcare utilization, and patient-reported barriers.
    RESULTS: Of 108 participants, 66 completed 12 week assessments and 59 were using CGM. At 24 weeks, data were available for 57 participants, 17 of whom maintained CGM use. Median HbA1c improved from baseline to 24 weeks (11.6% [IQR 10.0 to 13.4] to 7.4% [IQR 6.7 to 9.5], 103 to 57 mmol/mol, p < 0.0001), with similar reductions among users and non-users. Among CGM users, median time in range (TIR, 70 to 180 mg/dL) increased from 43% at 12 weeks to 62% at 24 weeks (p = 0.66), while time above range (TAR > 180 mg/dL) decreased from 57% to 37% (p = 0.67). Cost and insurance barriers were the most reported challenges (46%), occurring more often among those who discontinued versus continued CGM (75% vs 32%, p = 0.007).
    CONCLUSIONS: HbA1c improved from baseline to 24 weeks among participants, regardless of continued CGM use. However, discontinuation was common, with financial barriers representing the predominant obstacle, underscoring the need for improved coverage and support.
    Keywords:  continuous glucose monitoring; hospital discharge; type 2 diabetes
    DOI:  https://doi.org/10.1016/j.eprac.2026.02.013
  4. Br J Nurs. 2026 Feb 19. 35(4): 182-190
      This article explores the confidence, preparedness, and training of inpatient diabetes specialist nurses (DSNs) in managing continuous glucose monitoring (CGM) and hybrid closed loop (HCL) systems. Using data from a national survey conducted in May 2025, the study identified high confidence levels with CGM among inpatient DSNs, but lower confidence and training gaps regarding HCL systems. Thematic analysis revealed recurring challenges, including infrastructure limitations, role ambiguity and safety concerns. The authors recommend NHS-led training, improved digital access, standardised protocols and strengthened workforce planning to support the safe adoption of diabetes technology in hospital settings.
    Keywords:  Continuous glucose monitor (CGM); Diabetes specialist nurse (DSN); Hybrid closed loop (HCL) system; Inpatient care; Type 1 diabetes
    DOI:  https://doi.org/10.12968/bjon.2025.0578
  5. Diabetes Res Clin Pract. 2026 Feb 14. pii: S0168-8227(26)00079-3. [Epub ahead of print] 113160
       AIMS: Time in Tight Range (TITR) is an emerging continuous glucose monitoring (CGM) metric assessing time spent in the 70-140 mg/dL range. While TITR is increasingly recognized for reflecting optimal glucose control, its psychological impact remains unexplored. This study assessed the relationship between TITR and psychological outcomes in adolescents with type 1 diabetes (T1D).
    METHODS: This cross-sectional study included 123 adolescents with T1D. Participants completed two validated questionnaires: the PAID-Teen, which measures diabetes-related distress, and the PERMA model, which evaluates psychological well-being. CGM data were analyzed to determine participants' glucose metrics.
    RESULTS: Achieving TITR ≥ 50% was associated with higher distress scores (OR = 1.023; 95% CI 1.002-1.044; p = 0.029), while no such association was found with PERMA scores. Conversely, time in range (TIR) ≥ 70% showed no significant relationship with psychological outcomes.
    CONCLUSIONS: These findings suggest TITR may impose additional psychological burden beyond conventional glycemic targets. Further longitudinal studies are needed to evaluate its long-term impact on quality of life and optimize diabetes management strategies for youth with T1D.
    Keywords:  CGM metrics; Distress; PAID-Teen; Time in range; Well-being
    DOI:  https://doi.org/10.1016/j.diabres.2026.113160
  6. J Diabetes Sci Technol. 2026 Feb 16. 19322968261422250
       BACKGROUND: The use of Continuous Glucose Monitoring (CGM) devices has significantly improved diabetes management. However, several limitations persist, including the great variation in accuracy, inconsistent study designs, and variations in regulatory approval standards. Therefore, the need for regulatory harmonization, robust validation, and transparent data reporting is crucial.
    METHODS: The current consensus report was developed through a structured, multi-phase process to comprehensively assess these challenges. A literature review of databases such as PubMed, Scopus, and the Saudi Digital Library, focusing on publications from 2016 to 2024, evaluated evidence on CGM devices in terms of performance and clinical outcome, with priority given to regional data, randomized controlled trials (RCTs), and systematic reviews. A multidisciplinary panel reviewed the literature, engaging in structured discussions. Recommendations were formulated using the Delphi method, ensuring consensus and alignment with global standards while addressing regional challenges.
    RESULTS AND RECOMMENDATIONS: The resulting recommendations advocate for aligning Saudi regulatory standards with international frameworks like Food and Drug Administration iCGM criteria, Medical Device Regulation (MDR)-aligned criteria, establishing and enforcing minimum performance criteria, including dynamic testing for glucose fluctuations, strengthening local post-market surveillance capacity, mandating transparent data reporting by manufacturers, and facilitating comprehensive clinical education and cross-sector collaboration.
    Keywords:  Delphi method; continuous glucose monitoring; device accuracy; diabetes management; regulatory harmonization
    DOI:  https://doi.org/10.1177/19322968261422250
  7. Diabetes Technol Ther. 2026 Feb 16. 15209156261423902
       OBJECTIVE: Real-time continuous glucose monitoring (CGM) systems are beneficial for patients with diabetes by providing a comprehensive assessment of glycemic status and reducing hypoglycemia. However, their performance in patients with both diabetes and chronic kidney disease (CKD) during hospitalization remains unclear. This study aimed to evaluate the accuracy of real-time CGM in hospitalized patients with diabetes and CKD.
    RESEARCH DESIGN AND METHODS: We conducted a prospective observational study including 52 patients with diabetes after excluding those with acute kidney injury, active glomerulonephritis, requiring intensive care, or undergoing hemodialysis. Participants were categorized by estimated glomerular filtration rate (eGFR, mL/min/1.73 m2) into G1-2 (≥60), G3 (30-59), and G4-5 (<30). Capillary glucose values were measured with a validated point-of-care (POC) device and paired with corresponding real-time CGM (G6, Dexcom) readings. Accuracy was assessed by mean absolute relative difference (MARD), correlation analyses, Bland-Altman plots, and consensus error grid (CEG) analyses.
    RESULTS: A total of 1603 paired glucose values were analyzed, including 752 in G1/2, 571 in G3, and 280 in G4/5. CGM and POC glucose were strongly correlated (r = 0.91, P < 0.001). The overall MARD was 17.0%, with group-specific values of 19.4% in G1/2, 15.5% in G3, and 13.5% in G4/5 (P < 0.001). Bland-Altman plots showed smaller bias and narrower limits of agreement in advanced CKD. CEG analyses demonstrated high agreement, with >99% of values within clinically acceptable zones.
    CONCLUSIONS: The Dexcom G6 demonstrated reliable accuracy in hospitalized patients with diabetes and CKD, with better performance in advanced CKD. These findings support its clinical utility in this population.
    Keywords:  CKD; Dexcom G6; hospitalized patients; real-time CGM
    DOI:  https://doi.org/10.1177/15209156261423902
  8. Diabetes Technol Ther. 2026 Feb 17. 15209156261423954
       BACKGROUND: Continuous glucose monitoring (CGM) systems predominantly rely on oxygen-dependent enzymatic electrochemistry. While their accuracy is well established in normoxic conditions, little evidence exists regarding their performance during hypoxia, a situation encountered during altitude exposure, air travel, or specific medical conditions. This study assessed the accuracy of two widely used glucose-oxidase CGM systems (FreeStyle Libre® and Dexcom G6®) during controlled hypoxia.
    METHODS: In a randomized controlled study, healthy volunteers and participants with diabetes were exposed to standardized normobaric hypoxia (fraction of inspired oxygen of 14.5%). Participants simultaneously wore FreeStyle and Dexcom sensors. Venous plasma glucose, analyzed using the hexokinase method, served as the reference. To induce glycemic excursions, participants consumed a standardized mixed meal and performed moderate-intensity cycling exercise. The primary end point was the mean absolute relative difference (MARD) comparing CGM values with reference glucose. Secondary assessments included consensus error grid analysis (CEGA).
    RESULTS: Thirty participants were included (15 healthy volunteers and 15 with diabetes). Median age was 29.5 (interquartile range [IQR]: 23.0-41.0) years, and median body mass index was 23.3 (IQR, 22.0-26.4) kg/m2. Among participants with diabetes, 53% had type 1 diabetes and 47% type 2, with a median diabetes duration of 16.3 [IQR, 11.3-21.6] years and HbA1c of 7.5% [IQR, 6.6-7.8]. During hypoxia MARD values were 21.2% for FreeStyle and 41.8% for Dexcom in healthy volunteers and 11.8% and 17.5%, respectively, in participants with diabetes. CEGA showed that 97% of FreeStyle and 87% of Dexcom readings fell within zones A or B during hypoxia.
    CONCLUSIONS: Both CGM systems showed reduced accuracy under hypoxia, particularly during dynamic glycemic changes. Awareness of these limitations and selective confirmation with capillary testing can assist safe use when clinically relevant decisions are required. The implications for automated insulin delivery systems warrant further dedicated evaluation.
    Keywords:  accuracy; continuous glucose monitoring; diabetes; healthy volunteer; mean absolute relative difference; normobaric hypoxia
    DOI:  https://doi.org/10.1177/15209156261423954
  9. J Diabetes Investig. 2026 Feb 18.
       BACKGROUND: Diabetes distress is common in patients with type 1 diabetes mellitus (T1DM). The aim of this study was to construct and validate prediction models for diabetes distress in adults with T1DM using continuous glucose monitoring (CGM) metrics.
    METHODS: The CGM metrics were collected from 259 adults with T1DM. Severe diabetes distress was defined as 40 points on the Problem Areas in Diabetes scale. Prediction models were developed based on ten machine learning algorithms: random forest (RF), support vector machine (SVM), Naive Bayes (NB), Neural Network (NN), k-nearest neighbor (k-NN), XGBoost (XGB), SGDClassifier (SGDC), XGB_limitet_depth (CGB_ld), L1LogisticRegression (L1), and LightGBM. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, precision, recall, and F1 score.
    RESULTS: Among the ten models, accuracy in the NN model was the highest (NN: 0.744, L1: 0.731, NB: 0.718, SVM: 0.692, SGDC: 0.654, RF: 0.628, k-NN: 0.628, LightGBM: 0.615, XGBoost: 0.564, and XGB_ld: 0.564). The NN model achieved the highest AUC of 0.728 (95% confidence interval: 0.608-0.845).
    CONCLUSIONS: This study developed a predictive model for severe diabetes distress using machine learning, incorporating both demographic and CGM metrics in adults with type 1 diabetes mellitus. The NN model demonstrated potential as a practical tool to assist clinicians in identifying individuals at risk of severe diabetes distress.
    Keywords:  Machine learning; Neural Network; type 1 diabetes mellitus
    DOI:  https://doi.org/10.1111/jdi.70229
  10. Diabetes Metab Syndr. 2026 Feb 13. pii: S1871-4021(26)00003-2. [Epub ahead of print]20(2): 103376
       BACKGROUND: There is limited understanding of the impact of glucose monitoring technologies on relationships with food and eating behaviours for those with type 2 diabetes mellitus (T2DM).
    AIMS: With previous reviews focused on T2DM treatment burden and self-management, this review aims to enhance understanding of the impact of flash or continuous glucose monitoring (FGM/CGM) on users' eating behaviours and relationships with food as this can inform important recommendations for CGM use amongst those with T2DM.
    METHOD: A systematic search was conducted across four databases: Scopus, Medline, CINAHL and PubMed, from October-November 2024, following PRISMA guidelines. Studies were quality appraised and qualitative data was synthesized using thematic synthesis.
    FINDINGS: Thirteen studies met inclusion criteria and their findings were included in the synthesis. The review revealed that F/CGM enhanced participants' nutritional awareness, supported personalised dietary experimentation, and fostered intentional eating behaviours. However, data overload and emotional burden were also reported, with some users experiencing restrictive or distressing impacts on their relationship with food. These insights inform practical recommendations for CGM implementation with those with T2DM.
    CONCLUSION: Further research should aim to identify factors that contribute to successful adaptation to CGM and explore the long-term effects of CGM use on food relationships.
    Keywords:  Eating behaviour; Flash/continuous glucose monitoring; Qualitative research; Relationship with food; Type 2 diabetes mellitus
    DOI:  https://doi.org/10.1016/j.dsx.2026.103376
  11. Ned Tijdschr Geneeskd. 2026 Feb 17. pii: D8854. [Epub ahead of print]170
      Diabetes mellitus is a prevalent chronic condition with major impact on quality of life. Traditional treatment relied on insulin injections and self-monitoring, but advances in diabetes technology, such as continuous glucose monitoring (CGM), insulin pumps, and Hybrid Closed-Loop (HCL) systems, now provide new opportunities for optimizing glycemic control. HbA1c remains the established marker for long-term outcomes, though complementary use of Time in Range (TIR) offers more detailed insight into daily glucose variability. Clinical evidence shows that technologies such as CGM, HCL, and connected devices can reduce HbA1c, increase TIR, and lower the risk of severe hypoglycemia, while also improving quality of life and psychosocial outcomes. However, implementation must be tailored to individual patients, considering motivation, skills, and context. Future developments, including fully closed-loop systems, further highlight the need for clinicians to remain informed about rapidly evolving technologies and to critically assess their added value in daily practice.
  12. Diabetes Obes Metab. 2026 Feb 18.
       BACKGROUND: To investigate the triglyceride-glucose index (TyG) as a predictor of glycaemic variability phenotypes in patients with type 2 diabetes mellitus (T2DM) using continuous glucose monitoring (CGM)-derived metrics, guiding personalized management.
    MATERIALS AND METHODS: This cross-sectional study analysed 279 T2DM patients who underwent 14-day CGM monitering from community hospitals in Ningbo, China. Participants were stratified by TyG tertiles. Spectral clustering with complexity-invariant dynamic time warping identified distinct glycaemic variability glucotypes. Comprehensive CGM metrics spanning time-domain, frequency-domain, event-based, and circadian rhythm domains were evaluated. Multivariable logistic regression assessed associations between TyG and glycaemic phenotypes.
    RESULTS: Across TyG tertiles, we observed progressive increases in HbA1c (6.8 ± 1.5%, 7.2 ± 1.2%, 7.3 ± 1.3%, p = 0.011), fasting glucose (6.1 ± 1.1, 7.2 ± 1.6, 8.5 ± 2.8 mmol/L, p < 0.001), and triglycerides (0.9 ± 0.2, 1.4 ± 0.4, 2.7 ± 1.0 mmol/L, p < 0.001). Most notably, patients in the highest TyG tertile exhibited sustained hyperglycaemia with lower TIR (81.8% to 72.8 to 70.3%, p = 0.001), elevated TAR (15.9% vs. 29.1%, p < 0.001), and paradoxically reduced TBR (2.3% to 1.4% to 0.6%, p = 0.014) and CV (26.2% to 25.8% to 23.8%, p = 0.021). Frequency domain analysis demonstrated that elevated TyG was associated with high-level, low-frequency glucose oscillations. Higher TyG tertiles demonstrated increased prevalence of severe variability glucotype (32.3% to 53.8% to 63.4%), with TyG emerging as the strongest independent predictor (OR = 1.87, 95% CI: 1.42-2.50, p < 0.001).
    CONCLUSIONS: Elevated TyG identifies a distinct glycaemic phenotype characterized by high-level, low-frequency oscillations, sustained hyperglycaemia, and minimal hypoglycaemic risk. T2DM patients with high TyG levels may be appropriate candidates for more intensified glucose-lowering strategies.
    DOI:  https://doi.org/10.1111/dom.70558
  13. Diabetol Int. 2026 Apr;17(2): 24
       Aims/introduction: Severe hypoglycemia (SH) is a major complication in adults with type 1 diabetes mellitus (T1DM). The multifactorial etiology of T1DM highlights the need for predictive tools that integrate clinical, behavioral, and technological factors. This study aimed to develop and evaluate machine learning (ML) models for predicting SH by incorporating hypoglycemia problem-solving ability, diabetes technology, and continuous glucose monitoring (CGM) indices.
    Materials and methods: We analyzed data from 247 adults with T1DM (mean age 50.4 ± 13.7 years; 38.1% male; glycosylated hemoglobin 7.7 ± 0.9%) from the FGM-Japan study. A total of 22,517 feature-model combinations were evaluated across 11 ML algorithms, including logistic regression, L1-regularized regression, random forest, LightGBM, XGBoost, SVM, Naïve Bayes, SGD, neural networks, and k-nearest neighbors. Eleven candidate predictors included impaired awareness of hypoglycemia (IAH), diabetic peripheral neuropathy (DPN), CSII, rtCGM, and seven domains of hypoglycemia problem-solving ability. The model performance was assessed with fivefold cross-validation using the receiver operating characteristic-area under the curve (ROC-AUC), accuracy, precision, recall, and F1 score. Class imbalance was addressed using SMOTE.
    Results: The mean ROC-AUC across models was 0.64 (range: 0.151-0.916). The average accuracy was 0.90, but the precision and recall were consistently low, with a mean recall of 0.08. The high-performing models (ROC-AUC > 0.90) were primarily Random Forest and LightGBM, which frequently incorporated domains such as problem perception, identifying problem attributes, seeking preventive strategies, evaluating strategies, and immediate management. factors. Tree-based models significantly outperformed logistic regression, Naïve Bayes, SVM, and SGD (adjusted p < 0.001), whereas the differences among the tree-based algorithms were not clinically meaningful.
    Conclusions: Tree-based ML models demonstrated superior discriminative ability for predicting SH in patients with T1DM. Hypoglycemia problem-solving ability was the strongest predictor, underscoring the importance of integrating behavioral self-management skills with clinical and technological factors.
    Trial registration: University hospital Medical Information Network (UMIN) Center: UMIN000039475), Approval date 13 February 2020.
    Keywords:  Hypoglycemia problem-solving; Impaired awareness of hypoglycemia; Severe hypoglycemia; Type 1 diabetes
    DOI:  https://doi.org/10.1007/s13340-026-00875-9
  14. PLOS Digit Health. 2026 Feb;5(2): e0001229
      This study aims to characterize the temporal discordance between CGM-derived glucose exposure and HbA1c over time in individuals with type 1 diabetes, and to explore the development of a statistical model to adjust the relationship between these measures based on previously observed individual discrepancies. We paired CGM-data in a 60-day window prior to each HbA1c measurement and included individuals with type 1 diabetes with multiple pairs to assess and model discordance over time. Discordance was defined as difference between HbA1c and Glucose Management Indicator at each pair. At baseline (first pair), participants were categorized into three groups based on the degree of discordance: positive (≥0.5%), negative (≤-0.5%), and neutral (within ±0.5%). A multiple linear regression model incorporating historical discordance values, HbA1c levels, and the current GMI was utilized for an adjustment. 477 individuals were included and 1,523 instances of paired HbA1c and CGM-data were analyzed. Absolute discordance of ≥0.5% was observed in 31% of cases. In 51% of instances, the direction of discordance in each pair was maintained. In the modeling analysis, GMI accounted for 69% of the variance in HbA1c levels (r = 0.83, p < 0.001, MAE = 0.42%). Adjusting improved variance explainability to 82% (r = 0.90, p < 0.001, MAE = 0.33%). HbA1c-CGM discordance is highly prevalent, and while inter-individual discordance shows some degree of persistence, it also appears to vary over time for a substantial proportion of individuals. Adjusting for individual discordance in the short term can improve the alignment between adjusted GMI and laboratory-measured HbA1c.
    DOI:  https://doi.org/10.1371/journal.pdig.0001229
  15. J Pediatr Endocrinol Metab. 2026 Feb 19.
       OBJECTIVES: Despite proven benefits of diabetes technologies in children with type 1 diabetes (T1DM), utilization varies globally. In Hong Kong, continuous glucose monitoring system (CGMS) uptake was low (10.6 %) in 2018; however reimbursement programs have been implemented since then to enhance accessibility. This study examined trends in diabetes technology adoption and glycemic outcomes from 2018 to 2023.
    METHODS: The Hong Kong Childhood Diabetes Registry prospectively collected standardized data on all children with diabetes at age ≤18 years in public hospitals since 2018, and those with follow-up data between 2018 and 2023 were included. Regular CGMS use was defined as >80 % usage/year. Outcomes included mean HbA1c levels, incidence of diabetic ketoacidosis (DKA) and severe hypoglycemia. Clinical and psychosocial factors were compared between regular and non-regular CGMS users.
    RESULTS: Mean HbA1c significantly decreased from 8.3 % in 2018 to 8.0 % in 2023 (p<0.05), with fewer children having HbA1c >9 % and a reduced rate of DKA. Regular CGMS use increased from 10.7 to 41.7 %, with highest adoption among school-aged children and lowest among adolescents. Compared to non-regular users, regular CGMS users demonstrated better glycemic outcome (mean HbA1c 7.6 vs. 8.2 %, p<0.05). There were no significant differences in rates of micro/macrovascular complications or severe hypoglycemic events between the two groups.
    CONCLUSIONS: Despite improved glycemic outcomes and free access, CGMS adoption remained suboptimal in Hong Kong particularly among adolescents, indicating barriers beyond cost. Further research is needed to identify these barriers and develop targeted strategies to enhance technology use.
    Keywords:  children; continuous glucose monitoring; type 1 diabetes; utilization
    DOI:  https://doi.org/10.1515/jpem-2025-0595